Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Dimopoulos, M.A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K.C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C.K., et al. (2019). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The lancet, Vol.393 (10168), pp. 253-264.

Cook, G., Royle, K.-., Pawlyn, C., Hockaday, A., Shah, V., Kaiser, M.F., Brown, S.R., Gregory, W.M., Child, J.A., Davies, F.E., et al. (2019). A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. The lancet haematology, Vol.6 (3), pp. e154-e166.

Parzych, K., Saavedra-García, P., Valbuena, G.N., Al-Sadah, H.A., Robinson, M.E., Penfold, L., Kuzeva, D.M., Ruiz-Tellez, A., Loaiza, S., Holzmann, V., et al. (2019). The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. Oncogene, Vol.38 (17), pp. 3216-3231.

Messiou, C., Hillengass, J., Delorme, S., Lecouvet, F.E., Moulopoulos, L.A., Collins, D.J., Blackledge, M.D., Abildgaard, N., Østergaard, B., Schlemmer, H.-., et al. (2019). Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology, Vol.291 (1), pp. 5-13.  show abstract

Ahmed, N., Sriskandarajah, P., Burd, C., Riddell, A., Boyd, K., Kaiser, M. & Messiou, C. (2019). Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. The british journal of radiology, Vol.92 (1097), pp. 20180822-20180822.

Went, M., Sud, A., Li, N., Johnson, D.C., Mitchell, J.S., Kaiser, M. & Houlston, R.S. (2019). Regions of homozygosity as risk factors for multiple myeloma. Annals of human genetics, Vol.83 (4), pp. 231-238.

Jones, J.R., Weinhold, N., Ashby, C., Walker, B.A., Wardell, C., Pawlyn, C., Rasche, L., Melchor, L., Cairns, D.A., Gregory, W.M., et al. (2019). Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, Vol.104 (7), pp. 1440-1450.

Hoang, P.H., Cornish, A.J., Dobbins, S.E., Kaiser, M. & Houlston, R.S. (2019). Mutational processes contributing to the development of multiple myeloma. Blood cancer journal, Vol.9 (8).

Jackson, G.H., Davies, F.E., Pawlyn, C., Cairns, D.A., Striha, A., Collett, C., Waterhouse, A., Jones, J.R., Kishore, B., Garg, M., et al. (2019). Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The lancet haematology, .

Went, M., Kinnersley, B., Sud, A., Johnson, D.C., Weinhold, N., Försti, A., van Duin, M., Orlando, G., Mitchell, J.S., Kuiper, R., et al. (2019). Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. Human genomics, Vol.13 (1).

Shah, V., Sherborne, A.L., Walker, B.A., Johnson, D.C., Boyle, E.M., Ellis, S., Begum, D.B., Proszek, P.Z., Jones, J.R., Pawlyn, C., et al. (2018). Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia, Vol.32 (1), pp. 102-110.

Winfield, J.M., Poillucci, G., Blackledge, M.D., Collins, D.J., Shah, V., Tunariu, N., Kaiser, M.F. & Messiou, C. (2018). Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. European radiology, Vol.28 (4), pp. 1687-1691.

Shah, V., Johnson, D.C., Sherborne, A.L., Ellis, S., Aldridge, F.M., Howard-Reeves, J., Begum, F., Price, A., Kendall, J., Chiecchio, L., et al. (2018). Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, Vol.132 (23), pp. 2465-2469.  show abstract

Messiou, C. & Kaiser, M. (2018). Whole-Body Imaging in Multiple Myeloma. Magnetic resonance imaging clinics of north america, Vol.26 (4), pp. 509-525.

Boyle, E.M., Ashby, C., Wardell, C.P., Rowczenio, D., Sachchithanantham, S., Wang, Y., Johnson, S.K., Bauer, M.A., Weinhold, N., Kaiser, M.F., et al. (2018). The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood, Vol.132 (26), pp. 2775-2777.

Sriskandarajah, P., Pawlyn, C., Mohammed, K., Dearden, C.E., Davies, F.E., Morgan, G.J., Boyd, K.D. & Kaiser, M.F. (2017). The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. Leuk lymphoma, Vol.58 (2), pp. 494-497.

Pawlyn, C., Bright, M.D., Buros, A.F., Stein, C.K., Walters, Z., Aronson, L.I., Mirabella, F., Jones, J.R., Kaiser, M.F., Walker, B.A., et al. (2017). Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood cancer journal, Vol.7 (3), pp. e549-e549.

Johnson, D.C., Lenive, O., Mitchell, J., Jackson, G., Owen, R., Drayson, M., Cook, G., Jones, J.R., Pawlyn, C., Davies, F.E., et al. (2017). Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, Vol.130 (14), pp. 1639-1643.  show abstract

Moreau, P., Dimopoulos, M.A., Richardson, P.G., Siegel, D.S., Cavo, M., Corradini, P., Weisel, K., Delforge, M., O'Gorman, P., Song, K., et al. (2017). Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. European journal of haematology, Vol.99 (3), pp. 199-206.

Campbell, J.P., Heaney, J.L., Pandya, S., Afzal, Z., Kaiser, M., Owen, R., Child, J.A., Gregory, W., Morgan, G.J., Jackson, G.H., et al. (2017). Active multiple myeloma suppresses and typically eliminates coexisting MGUS. British journal of cancer, Vol.117 (6), pp. 835-839.

Li, N., Johnson, D.C., Weinhold, N., Kimber, S., Dobbins, S.E., Mitchell, J.S., Kinnersley, B., Sud, A., Law, P.J., Orlando, G., et al. (2017). Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. Cell reports, Vol.20 (11), pp. 2556-2564.

Shah, V., Boyd, K.D., Houlston, R.S. & Kaiser, M.F. (2017). Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. Bmc cancer, Vol.17 (1).

Went, M., Sud, A., Law, P.J., Johnson, D.C., Weinhold, N., Försti, A., van Duin, M., Mitchell, J.S., Chen, B., Kuiper, R., et al. (2017). Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood cancer j, Vol.7 (6), pp. e573-e573.

Wale, A., Pawlyn, C., Kaiser, M. & Messiou, C. (2016). Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma. Haematologica, Vol.101 (4), pp. e142-e144.

Pawlyn, C., Fowkes, L., Otero, S., Jones, J.R., Boyd, K.D., Davies, F.E., Morgan, G.J., Collins, D.J., Sharma, B., Riddell, A., et al. (2016). Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?. Leukemia, Vol.30 (6), pp. 1446-1448.

Mitchell, J.S., Li, N., Weinhold, N., Försti, A., Ali, M., van Duin, M., Thorleifsson, G., Johnson, D.C., Chen, B., Halvarsson, B.-., et al. (2016). Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nature communications, Vol.7 (1).

Brown, S., Hinsley, S., Ballesteros, M., Bourne, S., McGarry, P., Sherratt, D., Flanagan, L., Gregory, W., Cavenagh, J., Owen, R., et al. (2016). The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. Bmc hematology, Vol.16 (1).

Jones, J.R., Cairns, D.A., Gregory, W.M., Collett, C., Pawlyn, C., Sigsworth, R., Striha, A., Henderson, R., Kaiser, M.F., Jenner, M., et al. (2016). Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood cancer journal, Vol.6 (12), pp. e506-e506.

Dimopoulos, M.A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Di Raimondo, F., Weisel, K.C., Oriol, A., Hansson, M., Vacca, A., et al. (2016). Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood, Vol.128 (4), pp. 497-503.  show abstract

Johnson, D.C., Weinhold, N., Mitchell, J.S., Chen, B., Kaiser, M., Hillengass, J., Bertsch, U., Gregory, W.A., Cairns, D., Jackson, G.H., et al. (2016). Genome-wide association study identifies variation at 6q25 1 associated with survival in multiple myeloma. Nature communications, Vol.7.

Johnson, D.C., Weinhold, N., Mitchell, J., Chen, B., Stephens, O.W., Försti, A., Nickel, J., Kaiser, M., Gregory, W.A., Cairns, D., et al. (2016). Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia, Vol.30, pp. 883-888.

Li, N., Johnson, D.C., Weinhold, N., Studd, J.B., Orlando, G., Mirabella, F., Mitchell, J.S., Meissner, T., Kaiser, M., Goldschmidt, H., et al. (2016). Multiple myeloma risk variant at 7p15 3 creates an IRF4-binding site and interferes with CDCA7L expression. Nature communications, Vol.7.

Pawlyn, C., Kaiser, M.F., Heuck, C., Melchor, L., Wardell, C.P., Murison, A., Chavan, S.S., Johnson, D.C., Dahir, N.M., Proszek, P.Z., et al. (2016). The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clinical cancer research, Vol.22, pp. 5783-5794.

Boyle, E.M., Proszek, P.Z., Kaiser, M.F., Begum, D., Dahir, N., Savola, S., Wardell, C.P., Leleu, X., Ross, F.M., Chiecchio, L., et al. (2015). A Molecular Diagnostic Approach Able to Detect the Recurrent Genetic Prognostic Factors Typical of Presenting Myeloma. Genes chromosomes & cancer, Vol.54 (2), pp. 91-98.

Kühnl, A., Valk, P.J., Sanders, M.A., Ivey, A., Hills, R.K., Mills, K.I., Gale, R.E., Kaiser, M.F., Dillon, R., Joannides, M., et al. (2015). Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood, Vol.125 (19), pp. 2985-2994.  show abstract

Messiou, C. & Kaiser, M. (2015). Whole body diffusion weighted MRI - a new view of myeloma. British journal of haematology, Vol.171 (1), pp. 29-37.

Pawlyn, C., Melchor, L., Murison, A., Wardell, C.P., Brioli, A., Boyle, E.M., Kaiser, M.F., Walker, B.A., Begum, D.B., Dahir, N.B., et al. (2015). Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood, Vol.125 (5), pp. 831-840.  show abstract

Walker, B.A., Wardell, C.P., Murison, A., Boyle, E.M., Dahir, N.M., Proszek, P.Z., Melchor, L., Pawlyn, C., Kaiser, M.F., Johnson, D.C., et al. (2015). APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature communications, Vol.6.

Wu, P., Walker, B.A., Broyl, A., Kaiser, M., Johnson, D.C., Kuiper, R., van Duin, M., Gregory, W.M., Davies, F.E., Brewer, D., et al. (2015). A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. Leukemia & lymphoma, Vol.56, pp. 594-601.

Mitchell, J.S., Johnson, D.C., Litchfield, K., Broderick, P., Weinhold, N., Davies, F.E., Gregory, W.A., Jackson, G.H., Kaiser, M., Morgan, G.J., et al. (2015). Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Scientific reports, Vol.5.

Walker, B.A., Boyle, E.M., Wardell, C.P., Murison, A., Begum, D.B., Dahir, N.M., Proszek, P.Z., Johnson, D.C., Kaiser, M.F., Melchor, L., et al. (2015). Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. Journal of clinical oncology, Vol.33, pp. 3911-3920.

Walker, B.A., Wardell, C.P., Melchor, L., Brioli, A., Johnson, D.C., Kaiser, M.F., Mirabella, F., Lopez-Corral, L., Humphray, S., Murray, L., et al. (2014). Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia, Vol.28 (2), pp. 384-390.  show abstract

Pawlyn, C., Kaiser, M.F., Davies, F.E. & Morgan, G.J. (2014). Current and potential epigenetic targets in multiple myeloma. Epigenomics, Vol.6 (2), pp. 215-228.  show abstract

Pawlyn, C., Hookway, E., Cain, P., Pliuskys, L., Kaiser, M.F., Bright, M., Aronson, L.I., Murison, A., Lindow, M., Obad, S., et al. (2014). Histone Demethylase Inhibition As a Novel Therapeutic Strategy in Myeloma. Blood, Vol.124 (21).

Melchor, L., Brioli, A., Wardell, C.P., Murison, A., Potter, N.E., Kaiser, M.F., Fryer, R.A., Johnson, D.C., Begum, D.B., Hulkki Wilson, S., et al. (2014). Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia, Vol.28 (8), pp. 1705-1715.  show abstract

Pawlyn, C., Khan, M.S., Muls, A., Sriskandarajah, P., Kaiser, M.F., Davies, F.E., Morgan, G.J. & Andreyev, H.J. (2014). Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood, Vol.124 (15), pp. 2467-2468.

Brioli, A., Giles, H., Pawlyn, C., Campbell, J.P., Kaiser, M.F., Melchor, L., Jackson, G.H., Gregory, W.M., Owen, R.G., Child, J.A., et al. (2014). Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood, Vol.123 (22), pp. 3414-3419.  show abstract

Mirabella, F., Murison, A., Aronson, L.I., Wardell, C.P., Thompson, A.J., Hanrahan, S.J., Fok, J.H., Pawlyn, C., Kaiser, M.F., Walker, B.A., et al. (2014). A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. Plos one, Vol.9 (6), p. e99493.  show abstract

Mirabella, F., Wu, P., Wardell, C.P., Kaiser, M.F., Walker, B.A., Johnson, D.C. & Morgan, G.J. (2013). MMSET is the key molecular target in t(4;14) myeloma. Blood cancer j, Vol.3, p. e114.

Kaiser, M.F., Heider, U., Mieth, M., Zang, C., von Metzler, I. & Sezer, O. (2013). The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. Eur j haematol, Vol.90 (4), pp. 263-272.  show abstract

Kaiser, M.F., Heider, U., Mieth, M., Zang, C., von Metzler, I. & Sezer, O. (2013). The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. European journal of haematology, Vol.90 (4), pp. 263-272.

Brioli, A., Boyd, K.D., Kaiser, M.F., Pawlyn, C., Wu, P., Gregory, W.M., Owen, R., Ross, F.M., Jackson, G.H., Cavo, M., et al. (2013). Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. Br j haematol, Vol.161 (2), pp. 291-294.

Kaiser, M.F., Walker, B.A., Hockley, S.L., Begum, D.B., Wardell, C.P., Gonzalez, D., Ross, F.M., Davies, F.E. & Morgan, G.J. (2013). A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia, Vol.27 (8), pp. 1754-1757.

Wu, P., Agnelli, L., Walker, B.A., Todoerti, K., Lionetti, M., Johnson, D.C., Kaiser, M., Mirabella, F., Wardell, C., Gregory, W.M., et al. (2013). Improved risk stratification in myeloma using a microRNA-based classifier. British journal of haematology, Vol.162 (3), pp. 348-359.

Brioli, A., Kaiser, M.F., Pawlyn, C., Wu, P., Gregory, W.M., Owen, R., Ross, F.M., Jackson, G.H., Cavo, M., Davies, F.E., et al. (2013). Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leuk lymphoma, Vol.54 (9), pp. 1975-1981.  show abstract

Kaiser, M.F., Johnson, D.C., Wu, P., Walker, B.A., Brioli, A., Mirabella, F., Wardell, C.P., Melchor, L., Davies, F.E. & Morgan, G.J., et al. (2013). Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood, Vol.122 (2), pp. 219-226.  show abstract

Walker, B.A., Wardell, C.P., Johnson, D.C., Kaiser, M.F., Begum, D.B., Dahir, N.B., Ross, F.M., Davies, F.E., Gonzalez, D. & Morgan, G.J., et al. (2013). Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood, Vol.121 (17), pp. 3413-3419.  show abstract

Lamottke, B., Kaiser, M., Mieth, M., Heider, U., Gao, Z., Nikolova, Z., Jensen, M.R., Sterz, J., von Metzler, I. & Sezer, O., et al. (2012). The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur j haematol, Vol.88 (5), pp. 406-415.  show abstract

Morgan, G.J. & Kaiser, M.F. (2012). How to use new biology to guide therapy in multiple myeloma. Hematology am soc hematol educ program, Vol.2012, pp. 342-349.  show abstract

Huetter, G., Kaiser, M., Neumann, M., Mossner, M., Nowak, D., Baldus, C.D., Goekbuget, N., Hoelzer, D., Thiel, E. & Hofmann, W.-., et al. (2011). Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. Leukemia research, Vol.35 (5), pp. 614-619.

Kaiser, M., Kuehnl, A., Reins, J., Fischer, S., Ortiz-Tanchez, J., Schlee, C., Mochmann, L.H., Heesch, S., Benlasfer, O., Hofmann, W.-., et al. (2011). Antileukemic activity of the HSP70 inhibitor pifithrin-mu in acute leukemia. Blood cancer journal, Vol.1.

Kühnl, A., Gökbuget, N., Kaiser, M., Schlee, C., Stroux, A., Burmeister, T., Mochmann, L.H., Hoelzer, D., Hofmann, W.-., Thiel, E., et al. (2011). Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood, Vol.118 (24), pp. 6362-6367.  show abstract

Kühnl, A., Kaiser, M., Neumann, M., Fransecky, L., Heesch, S., Radmacher, M., Marcucci, G., Bloomfield, C.D., Hofmann, W.-., Thiel, E., et al. (2011). High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk res, Vol.35 (12), pp. 1585-1590.  show abstract

Heider, U., Rademacher, J., Kaiser, M., Kleeberg, L., von Metzler, I. & Sezer, O. (2010). Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin lymphoma myeloma leuk, Vol.10 (2), pp. 134-137.  show abstract

Kaiser, M., Lamottke, B., Mieth, M., Jensen, M.R., Quadt, C., Garcia-Echeverria, C., Atadja, P., Heider, U., von Metzler, I., Türkmen, S., et al. (2010). Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur j haematol, Vol.84 (4), pp. 337-344.  show abstract

Sterz, J., Jakob, C., Kuckelkorn, U., Heider, U., Mieth, M., Kleeberg, L., Kaiser, M., Kloetzel, P.-., Sezer, O. & von Metzler, I., et al. (2010). BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. Eur j haematol, Vol.85 (2), pp. 99-107.  show abstract

Heider, U., Kaiser, M., Mieth, M., Lamottke, B., Rademacher, J., Jakob, C., Braendle, E., Stover, D. & Sezer, O. (2009). Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur j haematol, Vol.82 (1), pp. 31-38.  show abstract

von Metzler, I., Krebbel, H., Kuckelkorn, U., Heider, U., Jakob, C., Kaiser, M., Fleissner, C., Terpos, E. & Sezer, O. (2009). Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase. J cancer res clin oncol, Vol.135 (2), pp. 173-179.  show abstract

von Metzler, I., Heider, U., Mieth, M., Lamottke, B., Kaiser, M., Jakob, C. & Sezer, O. (2009). Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. Exp cell res, Vol.315 (14), pp. 2471-2478.  show abstract

Kleeberg, L., Morgera, S., Jakob, C., Hocher, B., Schneider, M., Peters, H., Rötzer, S., Müller, C., Kaiser, M., Fleissner, C., et al. (2009). Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy. Eur j med res, Vol.14, pp. 47-54.  show abstract

Heider, U., von Metzler, I., Kaiser, M., Rosche, M., Sterz, J., Rötzer, S., Rademacher, J., Jakob, C., Fleissner, C., Kuckelkorn, U., et al. (2008). Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur j haematol, Vol.80 (2), pp. 133-142.  show abstract

Kaiser, M., Mieth, M., Liebisch, P., Oberländer, R., Rademacher, J., Jakob, C., Kleeberg, L., Fleissner, C., Braendle, E., Peters, M., et al. (2008). Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur j haematol, Vol.80 (6), pp. 490-494.  show abstract

Jakob, C., Sterz, J., Liebisch, P., Mieth, M., Rademacher, J., Goerke, A., Heider, U., Fleissner, C., Kaiser, M., von Metzler, I., et al. (2008). Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia, Vol.22 (9), pp. 1767-1772.  show abstract

Hecht, M., von Metzler, I., Sack, K., Kaiser, M. & Sezer, O. (2008). Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp cell res, Vol.314 (5), pp. 1082-1093.  show abstract

Schwarzer, R., Kaiser, M., Acikgoez, O., Heider, U., Mathas, S., Preissner, R., Sezer, O., Doerken, B. & Jundt, F. (2008). Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia, Vol.22 (12), pp. 2273-2277.

Jakob, C., Egerer, K., Liebisch, P., Türkmen, S., Zavrski, I., Kuckelkorn, U., Heider, U., Kaiser, M., Fleissner, C., Sterz, J., et al. (2007). Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood, Vol.109 (5), pp. 2100-2105.  show abstract

Hecht, M., Heider, U., Kaiser, M., von Metzler, I., Sterz, J. & Sezer, O. (2007). Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br j haematol, Vol.138 (4), pp. 446-458.  show abstract

von Metzler, I., Krebbel, H., Hecht, M., Manz, R.A., Fleissner, C., Mieth, M., Kaiser, M., Jakob, C., Sterz, J., Kleeberg, L., et al. (2007). Bortezomib inhibits human osteoclastogenesis. Leukemia, Vol.21 (9), pp. 2025-2034.  show abstract

Zavrski, I., Jakob, C., Kaiser, M., Fleissner, C., Heider, U. & Sezer, O. (2007). Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. Recent results cancer res, Vol.176, pp. 165-176.  show abstract

Zavrski, I., Kleeberg, L., Kaiser, M., Fleissner, C., Heider, U., Sterz, J., Jakob, C. & Sezer, O. (2007). Proteasome as an emerging therapeutic target in cancer. Curr pharm des, Vol.13 (5), pp. 471-485.  show abstract

Heider, U., Kaiser, M., Sterz, J., Zavrski, I., Jakob, C., Fleissner, C., Eucker, J., Possinger, K. & Sezer, O. (2006). Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur j haematol, Vol.76 (1), pp. 42-50.  show abstract

Kaiser, M., Zavrski, I., Sterz, J., Jakob, C., Fleissner, C., Kloetzel, P.-., Sezer, O. & Heider, U. (2006). The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica, Vol.91 (2), pp. 248-251.  show abstract

Jakob, C., Sterz, J., Zavrski, I., Heider, U., Kleeberg, L., Fleissner, C., Kaiser, M. & Sezer, O. (2006). Angiogenesis in multiple myeloma. Eur j cancer, Vol.42 (11), pp. 1581-1590.  show abstract

Heider, U., Fleissner, C., Zavrski, I., Kaiser, M., Hecht, M., Jakob, C. & Sezer, O. (2006). Bone markers in multiple myeloma. Eur j cancer, Vol.42 (11), pp. 1544-1553.  show abstract

Eucker, J., Sterz, J., Krebbel, H., Zavrski, I., Kaiser, M., Zang, C., Heider, U., Jakob, C., Elstner, E. & Sezer, O., et al. (2006). Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Anticancer drugs, Vol.17 (7), pp. 763-769.  show abstract

Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C.-., Fleissner, C., Hecht, M. & Sezer, O. (2006). Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur j haematol, Vol.77 (3), pp. 233-238.  show abstract

Heider, U., Kaiser, M., Mueller, C., Jakob, C., Zavrski, I., Schulz, C.-., Fleissner, C., Hecht, M. & Sezer, O. (2006). Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European journal of haematology, Vol.77 (3), pp. 233-238.

Zavrski, I., Jakob, C., Schmid, P., Krebbel, H., Kaiser, M., Fleissner, C., Rosche, M., Possinger, K. & Sezer, O. (2005). Proteasome: an emerging target for cancer therapy. Anticancer drugs, Vol.16 (5), pp. 475-481.  show abstract

Heider, U., Hofbauer, L.C., Zavrski, I., Kaiser, M., Jakob, C. & Sezer, O. (2005). Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem biophys res commun, Vol.338 (2), pp. 687-693.  show abstract

Zavrski, I., Krebbel, H., Wildemann, B., Heider, U., Kaiser, M., Possinger, K. & Sezer, O. (2005). Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem biophys res commun, Vol.333 (1), pp. 200-205.  show abstract

Weinhold, N., Johnson, D.C., Chubb, D., Broderick, P., Goldschmidt, H., Hemminki, K., Foersti, A., B, C., Hosking, F., Ma, Y., et al. The CCND1 G870A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nature genetics, .  show abstract

Walker, B.A., Wardell, , Brioli, A., Boyle, E., Kaiser, M.F., Begum, D.B., Dahir, N., Johnson, D.C., Ross, F.M., Davies, F.E., et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood csncer journal, Vol.14 (4), p. e191.  show abstract

Law, P.J., Sud, A., Houlston, R.S., Orlando, G., Broderick, P., Speedy, H.E., Johnson, D.C., Kaiser, M. & Swerdlow, A. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific reports, .

Hoang, P.H., Dobbins, S.E., Cornish, A.J., Chubb, D., Law, P.J., Kaiser, M. & Houlston, R.S. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia, .

Went, M. & Houlston, R.S. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nature communications, .

Johnson, D. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood advances, .

Pawlyn, C., Kaiser, M. & Jones, J. Lenalidomide maintenance for both transplant eligible and ineligible patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, .

Went, M., Sud, A., Speedy, H., Law, P., Johnson, D., Mirabella, F., Holroyd, A., Li, N., Orlando, G., Mitchell, J., et al. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood cancer journal, .

Lai, A.Y., Riddell, A., Barwick, T., Boyd, K., Rockall, A., Kaiser, M., Koh, D.-., Saffar, H., Yusuf, S. & Messiou, C., et al. Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. European radiology, .

Pawlyn, C., Cairns, D., Kaiser, M., Striha, A., Jones, J., Shah, V., Jenner, M., Drayson, M., Owen, R., Gregory, W., et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, .


Conferences

Kaiser, M., Dimopoulos, M.A., Gay, F., Schjesvold, F.H., Beksac, M., Hajek, R., Weisel, K.C., Goldschmidt, H., Maisnar, V., Moreau, P., et al. (2019). Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression-Free Survival Post-Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE-MM3 Trial, BRITISH JOURNAL OF HAEMATOLOGY, Vol.185, pp.18-19.

De Tute, R., Cairns, D., Rawstron, A., Pawlyn, C., Davies, F., Jones, J., Kaiser, M., Hockaday, A., Striha, A., Cook, G., et al. (2019). Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial, Clinical Lymphoma Myeloma and Leukemia, Vol.19 (10), pp.e45-e46.

Verkleij, C., Broekmans, M., van Duin, M., Frerichs, K., Kuiper, R., Kaiser, M., Morgan, G., Axel, A., Chiu, C., Sonneveld, P., et al. (2019). Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma, Clinical Lymphoma Myeloma and Leukemia, Vol.19 (10), pp.e122-e123.

Kaiser, M., Beksac, M., Gulbrandsen, N., Schjesvold, F., Hajek, R., Moreau, P., de Arriba, F., Mateos, M.-., West, S., Spencer, A., et al. (2019). Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM), Clinical Lymphoma Myeloma and Leukemia, Vol.19 (10), p.e293.

Bird, S., Sriskandarajah, P., Kaiser, M., Pawlyn, C. & Boyd, K. (2019). A ‘real-world’ study of panobinostat, bortezomib and dexamethasone in a very heavily pre-treated population of myeloma patients, Clinical Lymphoma Myeloma and Leukemia, Vol.19 (10), pp.e244-e245.

Mateos, M.-., Nahi, H., Legiec, W., Grosicki, S., Vorobyev, V., Spicka, I., Hungria, V.T., Korenkova, S., Bahlis, N.J., Flogegard, M., et al. (2019). Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA., JOURNAL OF CLINICAL ONCOLOGY, Vol.37 (15).

Sriskandarajah, P., Ahmed, N., Burd, C., Shah, V., Riddell, A., Boyd, K., Kaiser, M. & Messiou, C. (2018). Detection of asymptomatic femoral head avascular necrosis on routine whole body MRI in patients with multiple myeloma provides opportunities for joint preservation, BRITISH JOURNAL OF HAEMATOLOGY, Vol.181, p.98.

Austin, M., O'Connor, S., Morilla, R., Kaiser, M. & Boyd, K. (2018). False Negative Rate of Minimal Residual Disease Measurement by Multiparameter Flow Cytometry in Multiple Myeloma when Compared to Trephine Immunohistochemistry, Clinical Lymphoma Myeloma and Leukemia, Vol.18, pp.S243-S244.

Sriskandarajah, P., Macleod, K., Carragher, N., Kaiser, M.F. & Whittaker, S.R. (2018). Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis, ANNALS OF ONCOLOGY, Vol.29, p.7.

Croft, J., Hall, A., Walker, K., Sherborne, A.L., Boyd, K., Garg, M., Pawlyn, C., Sherratt, D., Reed, S., Pierceall, W.E., et al. (2018). Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone, Blood, Vol.132 (Supplement 1), p.4482.

Pawlyn, C., Jackson, G.H., Cairns, D., Striha, A., Hockaday, A., Jacques, G., Jones, J.R., Boyd, K., Kishore, B., Garg, M., et al. (2018). Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial, Blood, Vol.132 (Supplement 1), p.3280.

Shah, V., Johnson, D.C., Sherborne, A.L., Ellis, S., Price, A., Kendall, J., Chiecchio, L., Striha, A., Hockaday, A., Pawlyn, C., et al. (2018). Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials, Blood, Vol.132 (Supplement 1), p.2000.

Bygrave, C.A., Pawlyn, C., Davies, F.E., Cairns, D., Striha, A., Hockaday, A., Paterson, A., Jones, J.R., Kishore, B., Garg, M., et al. (2018). Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial, Blood, Vol.132 (Supplement 1), p.122.

Jackson, G.H., Davies, F.E., Pawlyn, C., Cairns, D., Striha, A., Hockaday, A., Collett, C., Jones, J.R., Kishore, B., Garg, M., et al. (2018). A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study, Blood, Vol.132 (Supplement 1), p.302.

Jackson, G.H., Davies, F.E., Pawlyn, C., Cairns, D.A., Striha, A., Collett, C., Waterhouse, A., Jones, J.R., Kishore, B., Garg, M., et al. (2016). Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study, Blood, Vol.128 (22), p.1143.

Popat, R., Brown, S.R., Tillotson, A.-., Collinson, F., Flanagan, L.M., Williams, C.D., Yong, K.L., Cook, G., Jenner, M.W., Kaiser, M., et al. (2016). A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial, Blood, Vol.128 (22), p.3321.

de Tute, R.M., Rawstron, A.C., Cairns, D.A., Pawlyn, C., Davies, F.E., Collett, C., Kaiser, M.F., Jones, J.R., Waterhouse, A., Striha, A., et al. (2016). Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial, Blood, Vol.128 (22), p.245.

Pawlyn, C., Kaiser, M.F., Stein, C.K., Wardell, C.P., Macleod, V., Edmondson, R., Barlogie, B., Walker, B., Morgan, G.J. & Davies, F.E., et al. (2015). Abstract 3516: EZH2 overexpression in myeloma patients shortens survival and in-vitro data supports a potential new targeted treatment strategy, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Experimental and Molecular Therapeutics, .

Raje, N., Chau, I., Hyman, D.M., Ribrag, V., Blay, J.-., Tabernero, J., Elena Elez-Fernandez, M., Wolf, J.S., Sirzen, F., Yee, A., et al. (2015). Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF(V600) Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study, BLOOD, Vol.126 (23).

Pawlyn, C., Chambers, T., Macleod, V., Sappington, D., Buros, A., Stein, C.K., Kaiser, M.F., Burke, R., Hoelder, S., Boysen, G., et al. (2015). Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines, BLOOD, Vol.126 (23).

Jones, J.R., Cairns, D.A., Sigsworth, R., Collett, C., Pawlyn, C., Striha, A., Melchor, L., Kaiser, M.F., Drayson, M.T., Davies, F.E., et al. (2015). Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases, BLOOD, Vol.126 (23).

Stein, C.K., Davies, F.E., Heuck, C., Weinhold, N., Chavan, S.S., Walker, B.A., Thanendrarajan, S., Epstein, J., Yaccoby, S., Zangari, M., et al. (2015). Molecular Subtyping and Risk Stratification for the Classification of Myeloma, BLOOD, Vol.126 (23).

Tornatore, L., Acton, G., Adams, N., Campbell, E.A., Kelly, J., Szydlo, R.M., Tarbit, M., Bannoo, S., D'Andrea, D., Capece, D., et al. (2015). Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3, Blood, Vol.126 (23), p.868.

Yong, K.L., Brown, S., Hinsley, S., Flanagan, L., Rabin, N., Ramasamy, K., Cavenagh, J., Owen, R.G., Kaiser, M.F., Low, E., et al. (2015). Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen, BLOOD, Vol.126 (23).

Pawlyn, C., Davies, F.E., Cairns, D.A., Collett, C., Chalmers, A., Striha, A., Jones, J.R., Garg, M., Allotey, D., Karunanithi, K., et al. (2015). Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients, BLOOD, Vol.126 (23).

Pawlyn, C., Kaiser, M.F., Fowkes, L., Jones, J.R., Davies, F.E., Morgan, G.J., Collins, D., Sharma, B., Riddell, A. & Messiou, C., et al. (2015). WB-DWI MRI Scanning Outperforms FDG PET-CT for the Assessment of Myeloma Disease Burden, BLOOD, Vol.126 (23).

Sriskandarajah, P., Pawlyn, C., Boyle, E., Mohammed, K., Ethell, M., Potter, M.N., Dearden, C., Davies, F.E., Morgan, G.J. & Kaiser, M.F., et al. (2015). Retrospective observational study of patients with relapsed/refractory myeloma treated with pomalidomide - the UK Experience, BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, pp.64-65.

Pawlyn, C., Davies, F., Cairns, D., Collett, C., Jones, J., Kaiser, M., Chalmers, A., Striha, A., Milligan, D., Lindsay, J., et al. (2015). THE QUADRUPLET COMBINATION OF CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE, AND DEXAMETHASONE IS SAFE AND WELL TOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MYELOMA PATIENTS, HAEMATOLOGICA, Vol.100, p.152.

Wale, A., Pawlyn, C., Kaiser, M. & Messiou, C. (2015). WHOLE BODY DIFFUSION WEIGHTED MRI SCANNING IN PATIENTS WITH MYELOMA. INCIDENTAL FINDINGS-THE ROYAL MARSDEN EXPERIENCE, HAEMATOLOGICA, Vol.100, p.88.

Palumbo, A., Moreau, P., Dimopoulos, M.A., Corradini, P., Cavo, M., Delforge, M., Weisel, K.C., Goldschmidt, H., Petrini, M., Kaiser, M.F., et al. (2015). OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY, HAEMATOLOGICA, Vol.100, pp.82-83.

Lonial, S., Delforge, M., Einsele, H., Moreau, P., Kaiser, M., Dimopoulos, M.A., Oriol, A., Gyger, M., Hilder, B., Ptaszynski, A.M., et al. (2015). The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Melchor, L., Jones, J.R., Lenive, O., Peterson, E.A., Brioli, A., Murison, A., Wardell, C.P., Kaiser, M.F., Proszek, P., Boyle, E.M., et al. (2015). Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing, Blood, Vol.126, p.371.

Kaiser, M.F., Boyle, E.M., Walker, B.A., Proszek, P., Johnson, D.C., Pawlyn, C., Jones, J.R., Savola, S., Owen, R.G., Drayson, M.T., et al. (2015). Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases, Blood, Vol.126, p.2981.

Kaiser, M.F., Boyle, E.M., Walker, B.A., Proszek, P., Johnson, D.C., Pawlyn, C., Jones, J.R., Savola, S., Owen, R.G., Drayson, M.T., et al. (2015). Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance-an Analysis of 1,036 Myeloma Trial Patients, Blood, Vol.126, p.2983.

Pawlyn, C., Khan, M.S., Davies, F.E., Sriskandarajah, P., Kaiser, M., Andreyev, J. & Morgan, G.J. (2014). TREATMENT WITH THE BILE-ACID SEQUESTRANT COLESEVELAM IMPROVES LENALIDOMIDE ASSOCIATED DIARRHOEA IN MYELOMA PATIENTS, HAEMATOLOGICA, Vol.99, p.382.

Boyle, E.M., Walker, B.A., Wardell, C.P., Murison, A., Melchor, L., Kaiser, M.F., Proszek, P., Dahir, N., Johnson, D.C., Pawlyn, C., et al. (2014). Mutational patterns and copy number changes at diagnosis are a powerful tool to predict outcome: result of the sequencing study of 463 newly diagnosed myeloma trial patients, Blood, Vol.124, p.637.

Kaiser, M.F., Boyle, E.M., Walker, B.A., Pawlyn, C., Proszek, P., Dahir, N., Johnson, D.C., Savola, S., Cairns, D.A., Gregory, W., et al. (2014). High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients, Blood, Vol.124, p.172.

Kaiser, M.F., Murison, A., Pawlyn, C., Boyle, E.M., Johnson, D.C., Walker, B.A., Wu, P., Dahir, N., Wardell, C.P., Proszek, P., et al. (2014). High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation, Blood, Vol.124, p.2189.

Kaiser, M.F., Proszek, P., Dahir, N., Walker, B.A., Savola, S., Boyle, E.M., Johnson, D.C., Cairns, D.A., Gregory, W., Jackson, G., et al. (2014). Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA, Blood, Vol.124, p.5168.

Pawlyn, C., Kaiser, M.F., Walker, B.A., Wardell, C.P., Murison, A., Johnson, D.C., Melchor, L., Boyle, E.M., Jones, J., Dahir, N., et al. (2014). The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact, Blood, Vol.124, p.2194.

Melchor, L., Murison, A., Boyle, E.M., Wardell, C.P., Jones, J., Kaiser, M.F., Pawlyn, C., Johnson, D.C., Proszek, P., Dahir, N., et al. (2014). The extent of intra-clonal genetic diversity within the myeloma clone is a predictive biomarker of progression and outcome after treatment, Blood, Vol.124, p.640.

Pawlyn, C., Melchor, L., Boyle, E.M., Brioli, A., Kaiser, M.F., Gregory, W., Drayson, M.T., Jackson, G., Ross, F.M., Child, J.A., et al. (2013). Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma, Blood, Vol.122 (21), p.529.

Kaiser, M.F., Begum, D., Proszek, P., Dahir, N., Gonzalez de Castro, D., Pawlyn, C., Brioli, A., Savola, S., Gregory, W., Owen, R.G., et al. (2013). A Rapid and Robust Molecular Diagnostic Approach For Multiple Myeloma – Results From a Large Trial Cohort, Blood, Vol.122 (21), p.3097.

Brioli, A., Campbell, J.P., Kaiser, M.F., Pawlyn, C., Jackson, G.H., Gregory, W., Owen, R.G., Child, J.A., Davies, F.E., Cavo, M., et al. (2013). Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity, Blood, Vol.122 (21), p.752.

Murison, A., Wardell, C.P., Johnson, D.C., Pawlyn, C., Mirabella, F., Melchor, L., Fenwick, K., Kozarewa, I., Davies, F.E., Walker, B.A., et al. (2013). Discovery of genome wide epigenetic programming in t (4; 14) multiple myeloma and in the progression from myeloma to plasma cell leukemia via methyl binding domain protein capture and sequencing, Blood, Vol.122, p.599.

Wu, P., Agnelli, L., Walker, B.A., Todoerti, K., Johnson, D.C., Kaiser, M., Wardell, C.P., Gregory, W.M., Davies, F.E., Brewer, D., et al. (2012). Improved Risk Stratification in Myeloma Using Microrna-Based Classifier, BLOOD, Vol.120 (21).

Kaiser, M.F., Walker, B.A., Wardell, C.P., Mirabella, F., Fryer, R.A., Johnson, D.C., Fenwick, K., Kozarewa, I., Davies, F.E. & Morgan, G.J., et al. (2012). High-Resolution, Genome Wide Analysis of DNA Methylation Provides Insights Into the Epigenetic Architecture of t(4;14) Myeloma, BLOOD, Vol.120 (21).

Kaiser, M.F., Johnson, D.C., Walker, B.A., Wu, P., Wardell, C.P., Davies, F.E. & Morgan, G.J. (2012). Genome-Wide Methylation and Gene Expression Analyses Identify Patients At High and Low Risk of Disease Progression, BLOOD, Vol.120 (21).

Brioli, A., Ross, F.M., Kaiser, M.F., Pawlyn, C., Wu, P., Gregory, W.M., Owen, R.G., Jackson, G.H., Cavo, M., Davies, F.E., et al. (2012). The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping, BLOOD, Vol.120 (21).

Kaiser, M.F., Heider, U., Mieth, M., Zustin, J., Kuehnl, A., von Metzler, I. & Sezer, O. (2012). Induction of CXCL1 in Osteoblasts by Myeloma Cells Promotes Migration of Osteoclast Precursors, BLOOD, Vol.120 (21).

Wu, P., Agnelli, L., Walker, B.A., Todoerti, K., Johnson, D.C., Kaiser, M., Wardell, C.P., Gregory, W.M., Davies, F.E., Brewer, D., et al. (2012). Improved Risk Stratification in Myeloma Using Microrna-Based Classifier, BLOOD, Vol.120 (21).

Kaiser, M.F., Johnson, D.C., Walker, B.A., Wu, P., Wardell, C.P., Davies, F.E. & Morgan, G.J. (2012). Genome-Wide Methylation and Gene Expression Analyses Identify Patients At High and Low Risk of Disease Progression, BLOOD, Vol.120 (21).

Kaiser, M., Kuehnl, A., Ortiz-Tanchez, J., Schlee, C., Mochmann, L.H., Heesch, S., Thiel, E. & Baldus, C.D. (2011). The HSP70 inhibitor Pifithrin-mu is highly active against myeloid and lymphoid leukemic cells, ONKOLOGIE, Vol.34, p.76.

Kuehnl, A., Kaiser, M., Heesch, S., Thiel, E. & Baldus, C. (2010). High expression of IGFBP2 in adult acute myeloid leukemia and association with drug resistance, ONKOLOGIE, Vol.33, pp.215-216.

Heider, U., Kaiser, M., Mieth, M., von Metzler, I. & Sezer, O. (2010). The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of mesenchymal stem cells via upregulation of vitamin D receptor signaling: Implications for multiple myeloma, ONKOLOGIE, Vol.33, p.186.

Kaiser, M., Kuehnl, A., Ortiz-Tanchez, J., Benlasfer, O., Schlee, C., Heesch, S., Thiel, E. & Baldus, C. (2010). Antileukemic Activity of the HSP70 Inhibitor Pifithrin-mu, BLOOD, Vol.116 (21), pp.1354-1355.

Jakob, C., Sterz, J., Mieth, M., Heider, U., Kaiser, M., Liebisch, P., Rademacher, J., Mueller, C. & Sezer, O. (2009). The Bone Marker ICTP Adds to the Prognostic Significance of the ISS in Symptomatic Multiple Myeloma, CLINICAL LYMPHOMA & MYELOMA, Vol.9, pp.S54-S55.

Kaiser, M., Lamottke, B., Jensen, M.R., Quadt, C., Garcia-Echeverria, C., Mieth, M., Heider, U. & Sezer, O. (2009). Synergistic Action of Heat-Shock Protein-90 Inhibitor NVP-AUY922 with Histone Deacetylase Inhibition, CLINICAL LYMPHOMA & MYELOMA, Vol.9, p.S129.

Goerke, A., Jakob, C., Sterz, J., Heider, U., Kaiser, M., Mieth, M., Mueller, C., Terpos, E. & Sezer, O. (2009). SERUM LEVELS OF TOTAL-RANKL IN MULTIPLE MYELOMA, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.94, pp.161-162.

Heider, U., Kaiser, M., Mieth, M., Rademacher, J., Lamottke, B., Jakob, C., Braendle, E., Stover, D. & Sezer, O. (2009). SERUM DKK1 IN MULTIPLE MYELOMA PATIENTS, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.94, p.159.

Jakob, C., Sterz, J., Liebisch, P., Heider, U., Kaiser, M., Mieth, M., Mueller, C. & Sezer, O. (2009). INCORPORATION OF THE BONE MARKER CARBOXY-TERMINAL TELOPEPTIDE OF TYPE-1 COLLAGEN (ICTP) INTO A COMBINED ISS-ICTP SCORE IMPROVES THE PROGNOSTIC SIGNIFICANCE OF THE ISS IN SYMPTOMATIC MULTIPLE MYELOMA, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.94, p.384.

Heider, U., Rademacher, J., Kaiser, M., von Metzler, I., Marquardt, K. & Sezer, O. (2009). Decrease in CD4+T Cells in Multiple Myeloma Patients Receiving Bortezomib, BLOOD, Vol.114 (22), p.1487.

Jakob, C., Wernecke, T., Sterz, J., Goerke, A., Heider, U., Kaiser, M., Mieth, M., Ziefle, S. & Sezer, O. (2009). An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma., BLOOD, Vol.114 (22), p.1096.

Jakob, C., Sterz, J., von Metzler, I., Kuckelkorn, U., Braun, H.A., Kaiser, M., Heider, U., Rademacher, J., Kleeberg, L., Kloetzel, P.M., et al. (2008). Bsc2118, a novel proteasome inhibitor, causes growth inhibition, cell cycle arrest and cyclin D1 degradation in mantle cell lymphoma (MCL) cell lines, ANNALS OF ONCOLOGY, Vol.19, p.175.

Sezer, O., Kaiser, M., Siegel, D., Prosser, I., Mateos, M.V., Kangas, M., Jalaluddin, M., Bourquelot, P., Blade, J., Miguel, J.S., et al. (2008). A PHASE IB, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN ADULT PATIENTS WITH MULTIPLE MYELOMA (MM), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.93, p.176.

Jakob, C., Liebisch, P., Heider, U., Kaiser, M., Sterz, J., Rademacher, J., Fleissner, C., Mueller, C. & Sezer, O. (2008). Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy., BLOOD, Vol.112 (11), p.940.

Sterz, J., Metzler, I.V., Kuckelkorn, U., Braun, H.A., Rotzer, S., Kaiser, M., Fleissner, C., Heider, U., Kloetzel, P.M., Sezer, O., et al. (2007). BSC2118, a novel proteasome inhibitor with in vitro anti-tumor activity in multiple myeloma, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.92 (6), p.152.

Jakob, C., Egerer, K., Liebisch, P., Kuckelkorn, U., Turkmen, S., Kaiser, M., Fleissner, C., Sterz, J., Heider, U., Kleeberg, L., et al. (2007). Circulating proteasome levels in multiple myeloma, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.92 (6), p.119.

Jakob, C., Liebisch, P., Egerer, K., Sterz, J., Kaiser, M., Roetzer, S., Heider, U., Rademacher, J., Fleissner, C., Kloetzel, P.M., et al. (2007). The bone resorption marker serum-ICTP and the circulating proteasome levels separate ISS-Stages 1-3 and are the most powerful prognostic factors, for overall survival in newly diagnosed symptomatic multiple myeloma, BLOOD, Vol.110 (11), pp.441A-442A.

Jakob, C., Sterz, J., von Metzler, I., Kuckelkom, U., Braun, H.A., Roetzer, S., Kaiser, M., Heider, U., Rademacher, J., Kloetzel, P.M., et al. (2007). The proteasome inhibitor BSc2118 causes growth inhibition, cell cycle arrest and cyclin D1 degradation in mantle cell lymphoma cell lines, BLOOD, Vol.110 (11), p.420A.

Sterz, J., Jakob, C., Kuckelkorn, U., Braun, H.A., Kaiser, M., Fleissner, C., Kleeberg, L., Heider, U., Possinger, K., Kloetzel, P.M., et al. (2006). BSc2118, a novel proteasome inhibitor, shows anti-tumor activity in multiple myeloma and mantle cell lymphoma., BLOOD, Vol.108 (11), p.991A.

Heider, U., Kaiser, M., Zavrski, I., Sterz, J., Jakob, C., Fleissner, C., Hecht, M., Kleeberg, L., Braun, C., Possinger, K., et al. (2006). Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma., BLOOD, Vol.108 (11), pp.710A-711A.

Zavrski, I., Hecht, M., Krebbel, H., Fleissner, C., Mieth, M., Kaiser, M., Heider, U., Jakob, C., Sterz, J., Possinger, K., et al. (2006). Bortezomib inhibits human osteoclastogenesis., BLOOD, Vol.108 (11), p.406A.

Rosche, M., Zavrski, I., Schmid, P., Kaiser, M., Elsmer, E., Possinger, K. & Sezer, O. (2006). Combined proteasome and histone deacetylase inhibition in breast cancer cell lines., BREAST CANCER RESEARCH AND TREATMENT, Vol.100, p.S71.

Zavrski, I., Kaiser, M., Rosche, M., Heider, U., Jakob, C., Fleissner, C., Possinger, K. & Sezer, O. (2005). Bortezomib (PS-341) sensitizes multiple myeloma cell lines to etoposide-induced apoptosis., BLOOD, Vol.106 (11), p.375B.

Jakob, C., Sterz, J., Kleeberg, L., Zavrski, L., Kaiser, M., Eucker, J., Heider, U., Possinger, K. & Sezer, O. (2005). Serum total-RANKL is elevated in patients with multiple myeloma, increases with ISS stage and decreases after induction therapy., BLOOD, Vol.106 (11), p.705A.

Kaiser, M., Heider, U., Zavrski, I., Sterz, J., Possinger, K. & Sezer, O. (2005). Valproic acid inihibts histone deacetylases and proliferation and induces cell cycle arrest and apoptosis in multiple myeloma., BLOOD, Vol.106 (11), p.374B.

Heider, U., Kaiser, M., Zavrski, I., Sterz, J., Jakob, C., Fleissner, C., Possinger, K. & Sezer, O. (2005). Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in mantle cell lymphoma and reduce VEGF production, BLOOD, Vol.106 (11), p.284B.

Heider, U., Kaiser, M., Muller, C., Schulz, C.O., Jakob, C., Zavrski, I., Eucker, J., Sterz, J., Kleeberg, L., Possinger, K., et al. (2005). Treatment of bortezomib increases osteoblast function in patients with multiple myeloma., BLOOD, Vol.106 (11), p.965A.

In this section

Publications Research Overview